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Incidence of Dyspnea and Assessment of
Cardiac and Pulmonary Function in Patients
With Stable Coronary Artery Disease Receiving
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Objectives We prospectively assessed cardiac and pulmonary function in patients with stable coronary artery disease (CAD)
treated with ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET (A Multi-Centre Randomised, Double-Blind,
Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With
Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease) study.
Background Ticagrelor reduces cardiovascular events more effectively than clopidogrel in patients with acute coronary syn-
dromes. Dyspnea develops in some patients treated with ticagrelor, and it is not known whether this is associ-
ated with changes in cardiac or pulmonary function.
Methods In all, 123 stable aspirin-treated CAD patients randomly received either ticagrelor (180 mg load, then 90 mg
twice daily; n  57), clopidogrel (600 mg load, then 75 mg daily; n  54), or placebo (n  12) for 6 weeks in a
double-blind, double-dummy design. Electrocardiography, echocardiography, serum N-terminal pro-brain natri-
uretic peptide, and pulmonary function tests were performed before (baseline) and 6 weeks after drug adminis-
tration and/or after development of dyspnea.
Results After drug administration, dyspnea was reported by 38.6%, 9.3%, and 8.3% of patients in the ticagrelor, clopi-
dogrel, and placebo groups, respectively (p  0.001). Most instances were mild and/or lasted 24 h, although
3 patients discontinued ticagrelor because of dyspnea. Eight of 22 and 17 of 22 ticagrelor-treated patients expe-
riencing dyspnea did so within 24 h and 1 week, respectively, after drug administration. In all treatment groups,
and in ticagrelor-treated patients with dyspnea, there were no significant changes between baseline and 6
weeks in any of the cardiac or pulmonary function parameters.
Conclusions Dyspnea is commonly associated with ticagrelor therapy, but was not associated in this study with any adverse
change in cardiac or pulmonary function. (A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group
Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With Clopidogrel and Placebo With Aspi-
rin as Background Therapy in Patients With Stable Coronary Artery Disease [ONSET/OFFSET]; NCT00528411) (J Am
Coll Cardiol 2010;56:185–93) © 2010 by the American College of Cardiology Foundation
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Ticagrelor and Dyspnea July 13, 2010:185–93Ticagrelor (formerly AZD6140),
the first reversibly binding oral
P2Y12 receptor antagonist, inhibits
activation of the P2Y12 receptor by
adenosine diphosphate (ADP) in a
noncompetitive fashion (1). The
action of ticagrelor differs from
that of the thienopyridines clopi-
dogrel and prasugrel, which re-
quire hepatic conversion to active
metabolites that bind irreversibly
to the platelet P2Y12 receptor (2).
Recently, in the PLATO (Platelet
Inhibition and Patient Outcomes)
study, ticagrelor was shown to be
more efficacious than clopidogrel
in the prevention of myocardial
nfarction and death after acute coronary syndrome (3). In 2
hase II studies, dyspnea was noted to occur as a side effect to
icagrelor in a dose-dependent fashion (4,5); and in the
LATO study, there was a 6% absolute excess of dyspnea in
icagrelor-treated patients compared with patients treated with
lopidogrel (3). The mechanism for this side effect is unknown,
lthough preliminary data indicate that ticagrelor has an
ff-target effect on adenosine reuptake (6), and it is known that
ntravenous adenosine infusion can cause transient dyspnea in
he absence of bronchoconstriction (7).
We report here results from the randomized, double-
lind assessment of the ONSET/OFFSET (A Multi-
entre Randomised, Double-Blind, Double-Dummy Par-
llel Group Study of the Onset and Offset of Antiplatelet
ffects of AZD6140 Compared With Clopidogrel and
lacebo With Aspirin as Background Therapy in Patients
ith Stable Coronary Artery Disease) study of the anti-
latelet effects of ticagrelor versus clopidogrel in patients
ith stable coronary artery disease, which was conducted
oth to characterize further the onset and offset of action of
icagrelor compared with clopidogrel (reported elsewhere
8]) and to prospectively assess cardiac and pulmonary
unction in ticagrelor- and clopidogrel-treated patients with
table coronary artery disease (CAD).
ethods
tudy population. Between October 17, 2007, and March 5,
009, 154 patients with documented stable CAD were
ntered into the study in centers in the U.S. and the United
ingdom. The appropriate institutional review boards ap-
roved the study protocol, and patients provided written
nformed consent before beginning study procedures.
Patients were eligible if they were 18 years of age or older
nd had documented CAD, defined as any of the following:
table angina pectoris with objective evidence of CAD,
istory of myocardial infarction, or history of cardiac revas-
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
AUC0–8  area-under-the-
plasma concentration time
curve over 8 hours
CAD  coronary artery
disease
Cmax  maximum plasma
drug concentration
CYP  cytochrome P450
FEV1  forced expiratory
volume at 1 s
FVC  forced vital capacityularization. Patients were also required to have been taking daily aspirin therapy (75 to 100 mg). Exclusion criteria were
s follows: history of acute coronary syndromes in the past
ear; prior diagnosis by a physician of congestive heart
ailure, chronic obstructive pulmonary disease, chronic or
ctive asthma, or other cardiopulmonary disease that could
ffect the interpretation of cardiopulmonary data; cardiac
jection fraction 35%; forced expiratory volume in 1 s
FEV1) or forced vital capacity (FVC) below the lower limit
f the normal age- and sex-adjusted range at baseline; use of
obacco products in the last month; and current use of any
oderate or strong cytochrome P450 (CYP) 3A inhibitors,
trong CYP 3A inducers, or CYP 3A substrates with a
arrow therapeutic index.
tudy design. The complete study design is presented
lsewhere (8). Briefly, eligible patients were randomly as-
igned to receive either ticagrelor (90-mg tablet) or clopi-
ogrel (75-mg capsule) in an approximately 1:1 double-
lind, double-dummy fashion, although a smaller proportion
f patients were also randomly allocated to receive placebo.
icagrelor patients were given a loading dose of ticagrelor 180
g (two 90-mg tablets) as well as 8 clopidogrel placebo
apsules followed by a ticagrelor 90-mg tablet 12 h later.
atients were then given ticagrelor 90 mg twice daily and
lopidogrel placebo once in the morning for 6 weeks. Clopi-
ogrel patients received a 600-mg loading dose (eight 75-mg
apsules) as well as 2 ticagrelor placebo tablets followed by a
urther ticagrelor placebo tablet 12 h later. Thereafter, patients
ere administered 75-mg clopidogrel once daily and ticagrelor
lacebo twice daily for the duration of the study. Placebo
atients received loading doses of both dummy agents, fol-
owed by 1 ticagrelor placebo after 12 h and then ticagrelor and
lopidogrel placebo doses for the remaining 6 weeks. All
atients continued on background aspirin therapy (75 to 100
g once a day) during the treatment period. Patients were
ollowed up for 10 days after discontinuation of study drug and,
f necessary, were contacted after this time point to determine
he duration of adverse events.
The primary objectives of the main study were to deter-
ine the onset and offset of the antiplatelet effect of
icagrelor relative to clopidogrel, and the sample size was
etermined accordingly (8). The pre-specified subanalysis
eported in this paper was designed to determine whether
icagrelor therapy is associated with any significant change
n cardiopulmonary function and included all patients who
eceived at least 1 dose of study drug. In support of this
bjective, investigators were required to record as an adverse
vent any reports of shortness of breath occurring either at
est or on exertion (referred to here as dyspnea).
All adverse events, including dyspnea, were graded as
ild (awareness of sign or symptom but easily tolerated),
oderate (discomfort sufficient to cause interference with
ormal activities), or severe (incapacitating, with inability to
erform normal activities). Investigators were also required
o indicate whether they thought adverse events, including
yspnea, were possibly or likely related to study medication.
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July 13, 2010:185–93 Ticagrelor and Dyspneaardiac and pulmonary assessment. Cardiac and pulmo-
ary function were assessed at baseline (before study med-
cation) and after 6 weeks of treatment. Patients were
equested to contact the investigator if they had shortness of
reath after commencing study medication to allow the
cheduling of earlier assessment. Cardiac measurements
ncluded sitting blood pressure, heart rate, electrocardiogra-
hy, echocardiographic assessment of left ventricular ejection
raction, and N-terminal pro-brain natriuretic peptide. Pulmo-
ary function parameters included FEV1, FVC, FEV1/FVC,
ean forced expiratory flow between 25% and 75% of the
VC (FEF25–75), lung volume (forced residual capacity), total
ung capacity (TLC), residual volume , minute ventilation,
idal volume, respiratory rate, single-breath diffusing capacity
f lung for carbon monoxide, and oxygen saturation.
erum biochemistry. Serum samples were collected at
aseline, after 6 weeks of study medication, and 10 days
fter last dose of study medication. Additional serum
amples were also collected if patients experienced dyspnea.
nalysis of serum biochemistry was performed at local
aboratories. The results for serum bicarbonate are presented
ere, because it acts as a marker of metabolic and respiratory
H homeostasis and is, therefore, relevant to possible
tiology of dyspnea and pulmonary function.
harmacokinetic studies. Plasma levels of ticagrelor and
R-C124910XX, an active metabolite, were measured us-
ng validated bioanalytical methods by York Bioanalytical
olutions (York, United Kingdom). Pharmacokinetic pa-
ameters were assessed during onset and offset of study drug
ffect and included maximum plasma drug concentration
Cmax) and area-under-the-plasma concentration time curve
ver 8 h post-dosing (AUC0–8).
tatistical analysis. Statistical analyses were performed by
DS (King of Prussia, Pennsylvania) under the direction of
iostatistics at AstraZeneca (Wilmington, Delaware) using
AS version 8.0 (SAS Institute Inc., Cary, North Carolina).
isher’s exact test was used to compare proportions with
yspnea in the different groups and categorical demographic
ata. For the cardiopulmonary parameters, analysis was
erformed by the analysis of covariance model for each
ardiopulmonary function percentage change from baseline,
tting fixed-effect term for treatment group, with center and
enter-by-treatment interaction as covariates. Serum bicar-
onate levels, cardiac, and pulmonary data also were sum-
arized by descriptive statistics for all patients and were
lotted across time points for patients with a dyspnea event.
harmacokinetic parameters for ticagrelor and its active
etabolite AR-C124910XX and plasma concentration data
ere summarized using descriptive statistics, including geo-
etric mean and coefficient of variations. Log-transformed
max and AUC0–8 for ticagrelor and AR-C124910XX were
nalyzed using a t test between ticagrelor-treated patients
ith and without dyspnea.
Vesults
tudy population. In all, 154 patients were screened and
rovided informed consent; of these, 123 were randomized
o study treatment and were included in the safety cohort,
hich was used for the analysis of cardiac and pulmonary
unction. The treatment groups were generally well bal-
nced with respect to demographic and other baseline
haracteristics although there were nonsignificant trends
oward differences between the groups in proportions of
atients who had diabetes mellitus or were receiving
alcium-channel blockers and nitrates (Table 1).
ncidence of dyspnea. After study drug administration,
yspnea was reported by 38.6%, 9.3%, and 8.3% of patients
n the ticagrelor, clopidogrel and placebo groups, respec-
ively (ticagrelor vs. clopidogrel, p  0.001; ticagrelor vs.
lacebo, p  0.05; clopidogrel vs. placebo, p  NS).
yspnea judged by the investigator to be likely or possibly
ue to the study drug occurred in 24.6%, 3.7%, and 0% in
he ticagrelor, clopidogrel, and placebo groups, respectively
ticagrelor vs. clopidogrel, p  0.01). The timing, duration,
nd severity of the dyspnea in the different groups are
llustrated in Figure 1. Only 3 cases of dyspnea in the
icagrelor group and 1 case in the clopidogrel group were
udged to be moderate, whereas the rest were mild in
ntensity. Eight of 22 cases of dyspnea in the ticagrelor
roup occurred within 24 h of ticagrelor administration, and
7 of 22 of the cases occurred within 1 week. In contrast,
of 5 dyspnea cases in the clopidogrel group occurred 1
emographic and Baseline Characteristicsccording to Treatment GroupTable 1 Demograph c and B seline CharacteristicsAccording to Treatment Group
Characteristic
Ticagrelor
(n  57)
Clopidogrel
(n  54)
Placebo
(n  12)
Age (yrs)
Mean  SD 62 9 65 8 64 8
Range 41–79 42–83 44–79
Female 14 (25) 14 (26) 2 (17)
Race
Caucasian 51 (90) 48 (89) 9 (75)
Black/African American 4 (7) 5 (9) 3 (25)
Asian 1 (2) 1 (2) 0 (0)
Hawaiian 1 (2) 0 (0) 0 (0)
Former smoker 29 (51) 27 (50) 7 (58)
Dyslipidemia 54 (95) 52 (96) 12 (100)
Hypertension 44 (77) 39 (72) 9 (75)
Diabetes mellitus 12 (21) 10 (19) 5 (42)
Concomitant medications
Statins 49 (86) 50 (93) 11 (92)
Beta-blockers 39 (68) 42 (78) 9 (75)
Diuretics 20 (35) 18 (33) 4 (33)
Calcium-channel blocker 17 (30) 9 (17) 2 (17)
ACE inhibitors 10 (18) 8 (15) 2 (17)
Organic nitrates 6 (11) 12 (22) 0 (0)
Proton pump inhibitor 16 (28) 16 (30) 3 (25)alues are n (%) unless otherwise indicated. All p values  NS for ticagrelor versus clopidogrel.
ACE  angiotensin-converting enzyme.
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Ticagrelor and Dyspnea July 13, 2010:185–93eek after clopidogrel administration. Some cases lasted
24 h whereas others persisted over the course of the study,
ith most of these cases in the ticagrelor group resolving
pon cessation of ticagrelor administration. In 1 case in the
lacebo group, 2 cases in the clopidogrel group, and 3 cases
n the ticagrelor group, dyspnea was persistent at the end of
he study follow-up. Three ticagrelor patients experiencing
yspnea discontinued treatment as a result of this, compared
ith no patients taking clopidogrel or placebo.
ardiac and pulmonary function. There were no obvious
hanges in any of the cardiac measurements, including
lood pressure, heart rate, ejection fraction, and N-terminal
ro-brain natriuretic peptide, in any of the groups between
aseline and week 6 (Table 2). As expected in this popula-
ion, electrocardiograms at baseline showed a wide range of
bnormalities, and there were no adverse trends noted in
ny of the groups during the course of the study (data not
*
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Study Drug Administration Period (42 3
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Figure 1 Timing, Duration, and Severity of Dyspnea in Placebo,
Subjects administered placebo (n  1), clopidogrel (n  5), and ticagrelor (n  22
ication was administered on day 1 and continued until day 40 to 46. Episodes of
are denoted by solid lines. Green lines  mild dyspnea; red lines  moderate dys
min; green blocks and red blocks  premature discontinuation of drug.
ardiac Function AssessmentTable 2 Cardiac Function Assessment
Parameter
Ticagrelor (n  57)
Baseline 6 Weeks
Systolic BP, mm Hg 132 17 132 17
Diastolic BP, mm Hg 77 10 77 10
Heart rate, beats/min 66 11 66 13
Ejection fraction, % 58 9 61 8
NT-proBNP, pmol/ml 163 184 140 170alues are mean  SD.
BP  blood pressure; NT-proBNP  N-terminal pro-brain natriuretic peptide.hown). Similarly, there were no obvious changes in any of
he pulmonary parameters, including measures of ventila-
ion and respiratory rate, spirometry, lung volume, lung
iffusion capacity, and blood oxygen saturation, between the
time points in any of the groups (Table 3). Statistical
nalysis of percent change from baseline for all the cardiac
nd pulmonary measurements showed there was no statis-
ically significant difference between any of the treatment
roups, and there was no significant effect of center or center
y treatment interaction (data not shown).
In the cohort of patients who had dyspnea, study treat-
ent did not affect any of the cardiac measurements or
ulmonary parameters (Figs. 2A to 2I, Table 4). A small
umber of patients had additional cardiac and pulmonary
ssessments conducted at extra visits for assessment of
yspnea between baseline and 6 weeks. Six ticagrelor-
reated patients had early assessment of cardiac and pulmo-
)
40 45 50 55
Mild dyspnea
Moderate 
dyspnea
Mild dyspnea 
of ≤4 hours
Moderate 
dyspnea 
lasting 5 
minutes
Prematurely 
discontinued 
drug
*
idogrel, and Ticagrelor Groups
had any episode of dyspnea are indicated by the faint dashed lines. Study med-
nt dyspnea are denoted by markers, and more sustained or repeated episodes
green diamonds  mild dyspnea 4 h; blue asterisk  moderate dyspnea of 5
Clopidogrel (n  54) Placebo (n  12)
seline 6 Weeks Baseline 6 Weeks
 16 132 17 125 20 121 16
 10 74 11 71 9 70 7
 10 63 11 70 11 65 10
 8 62 7 60 10 61 10
 227 214 313 145 145 141 145y Day
 days
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July 13, 2010:185–93 Ticagrelor and Dyspneaary function as a result of dyspnea, and there was no
vidence of any adverse trends (Table 5). In particular, there
as no evidence on spirometry of transient bronchospasm in
he ticagrelor-treated patients, even in 2 of the patients who
iscontinued study medication due to dyspnea (individual
ata not shown separately).
erum bicarbonate levels. Serum bicarbonate levels showed
o significant evidence of metabolic acidosis developing after
tudy drug administration. Mean serum bicarbonate levels at
aseline, at 6 weeks, and at 10 days after dose were 27.2 2.2
mol/l, 26.2  2.3 mmol/l, and 27.2  2.3 mmol/l, respec-
ively, in the ticagrelor group; 27.5  1.9 mmol/l, 26.5  2.5
mol/l, and 27.1  2.5 mmol/l, respectively, in the clopi-
ogrel group; and 26.3 2.6 mmol/l, 26.4 3.3 mmol/l, and
7.6  2.1 mmol/l, respectively, in the placebo group. For
atients who experienced dyspnea during the study, the mean
erum bicarbonate levels at baseline, at 6 weeks, and at 10 days
fter dose were 27.0  2.6 mmol/l, 25.4  2.1 mmol/l, and
6.8 2.4 mmol/l, respectively, in the ticagrelor group; 26.5
.84 mmol/l, 25.2  4.7 mmol/l, and 28.5  1.0 mmol/l,
espectively, in the clopidogrel group; and for the 1 patient
ith dyspnea in the placebo group, 25.0 mmol/l, 29.0 mmol/l,
nd 29.0 mmol/l, respectively. Seven patients in the ticagrelor
roup who had dyspnea in the first 24 h had serum bicarbonate
easured at 24 h after the first dose and had serum bicarbonate
evels of 26.3  3.2 mmol/l at this time point.
elationship between dyspnea and pharmacokinetic
ata. Differences between pharmacokinetic parameters
max and AUC0–8 in the ticagrelor group were not statis-
ically significant between dyspnea and nondyspnea groups
t drug onset (first dosing) or offset (last dosing), although
here was a nonsignificant trend toward higher ticagrelor
evels in the patients with dyspnea: geometric mean (coef-
cient of variation) Cmax at onset was 1,249 ng/ml (24%) in
ulmonary Function AssessmentTable 3 Pulmonary Function Assessment
Parameter
Ticagrelor (n  57)
Baseline 6 Weeks
FEV1, l 2.8 0.7 2.8 0.7
FVC, l 3.7 0.9 3.7 0.9
FEV1/FVC 75 7 75 6
FEF25–75, % 2.9 1.3 2.8 1.3
VE, l/min 12.9 4.0 13.7 3.6 1
VT, l/min 0.96 0.33 0.92 0.26 0
FRC, l 2.8 0.9 2.7 0.7
TLC, l 5.8 1.3 5.7 1.2
RV, l 1.9 0.8 1.9 0.6
RR, breaths/min 15 2 15 3
DLCOSB, % 17 9 16 8
SpO2, % 97 2 98 1
alues are mean  SD.
DLCOSB  single-breath diffusing capacity of lung for carbon monoxide; FEF25–75 mean forced
orced residual capacity; FVC  forced vital capacity; RR  respiratory rate; RV  residual volume
entilation; VT  tidal volume.atients with dyspnea and 1,170 ng/ml (46%) in patients oithout dyspnea (p  0.54); at offset, the values were 890
g/ml (50%) and 669 ng/ml (59%), respectively (p  0.07).
ean AUC0–8 at onset was 5,903 ng·h
1·ml1 (23%) in
atients with dyspnea and 5,351 ng·h1·ml1 (43%) in
atients without dyspnea (p  0.33); at offset, mean
UC0 – 8 was 5,003 ng·h
1·ml1 (53%) and 3,772
g·h1·ml1 (61%), respectively (p 0.081). No differences
etween dyspnea and nondyspnea groups were seen with
espect to the plasma concentrations of AR-C124910XX,
n active metabolite of ticagrelor, and there was no trend
oward higher levels in the dyspnea group (data not shown).
iscussion
his is the first study to prospectively examine cardiac and
ulmonary function before and during treatment with
icagrelor. As in previous studies of ticagrelor in patients
ith atherosclerotic disease (3–5), dyspnea was observed in
significant proportion of patients after commencement of
icagrelor. The incidence of dyspnea in ticagrelor-treated
atients was greater in this study than in previous studies,
hich could be due to chance or could reflect the fact that
oth investigators and patients were informed of the poten-
ial occurrence of dyspnea and the reasons for cardiac and
ulmonary investigation, thus increasing their awareness of
he symptom and the probability of recording this as an
dverse event. Some of the episodes were mild and so
ransient that it is quite likely these could have been
verlooked in previous clinical studies, either because of lack
f awareness of this side effect in the first phase 2 study in
table patients (4) or because of the numerous other distrac-
ions in the early phase of treatment in the 2 acute coronary
yndrome studies (3,5). The pattern of dyspnea varied
idely, from very brief episodes lasting minutes to sustained
Clopidogrel (n  54) Placebo (n  12)
ine 6 Weeks Baseline 6 Weeks
0.8 2.7 0.8 2.9 0.7 3.0 0.7
1.1 3.8 1.0 4.0 0.9 4.0 0.9
7 73 6 73 7 74 8
1.2 2.7 1.2 2.5 1.2 2.9 1.4
3.6 13.1 5.5 12.1 4.1 11.5 3.5
0.32 0.93 0.39 0.89 0.27 0.83 0.33
0.9 2.8 0.9 2.9 0.7 2.78 1.0
1.4 5.9 1.4 6.1 1.0 6.0 1.4
0.6 2.0 0.6 1.9 0.4 1.9 0.8
3 15 2 16 2 15 1
11 17 8 16 6 16 7
2 97 1 98 1 99 1
tory flow between 25% and 75% of the FVC; FEV1  forced expiratory volume in 1 second; FRC 
 blood oxygen saturation measured by pulse oximetry; TLC  total lung capacity; VE  minuteBasel
2.8
3.7
73
2.7
2.2
.89
2.9
5.8
2.0
14
17
97
expirar intermittent episodes occurring over several weeks, with
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Ticagrelor and Dyspnea July 13, 2010:185–93ost episodes being reported as mild but some leading to
iscontinuation of study medication. Most of the sustained
pisodes in the ticagrelor group resolved upon cessation of
icagrelor, and there was little difference between the 2
ctive treatment groups in the proportions of patients who
ad persistent dyspnea despite discontinuation of the study
Figure 2 Cardiac and Pulmonary Parameters in Ticagrelor- and
Measurements were made at baseline before drug administration and after 6 wee
tion fraction (EF). (B) Forced expiratory volume in 1 s (FEV1). (C) Forced vital capa
(TLC). Continued on next page.edication. These observations provide reassurance about phe reversibility of ticagrelor-related dyspnea with decline in
lasma levels of ticagrelor.
To determine whether ticagrelor induced any changes in
ardiac function, we performed measurements of heart rate
nd electrical activity, blood pressure, left ventricular ejec-
ion fraction, and serum N-terminal pro-brain natriuretic
idogrel-Treated Patients With Dyspnea
reatment with ticagrelor 90 mg twice daily or clopidogrel 75 mg daily. (A) Ejec-
C). (D) Minute ventilation (VE). (E) Tidal volume (VT). (F) Total lung capacityClop
ks of t
city (FVeptide and found no significant changes in any of these
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July 13, 2010:185–93 Ticagrelor and Dyspneaeasurements during treatment, even in patients who had
yspnea after commencing ticagrelor. In addition, a wide
ange of parameters assessing different aspects of pulmonary
unction were examined, including established markers for
ssessing the presence and severity of bronchoconstriction
nd interstitial lung disease, and again, none of these
arameters showed any significant change during treatment
ith ticagrelor, including in patients with ticagrelor-related
yspnea. There was also no evidence that metabolic acido-
is, a cause of dyspnea, was induced by ticagrelor therapy as
udged by serum bicarbonate levels.
Phase II studies of ticagrelor demonstrated that the
ncidence of ticagrelor-related dyspnea is dose dependent,
uggesting that plasma levels of ticagrelor and/or its metab-
lites influence the likelihood of an individual developing
his side effect (4,5). In this study, there was only a
onsignificant trend toward higher ticagrelor levels in pa-
ients who had dyspnea compared with patients who did
ot, suggesting that factors other than plasma ticagrelor
evel play a substantial role in the likelihood of ticagrelor-
Figure 2 Continued
(G) Respiratory rate (RR). (H) Single-breath diffusing capacity for the lungs using c
(SpO2). The boxes represent the interquartile ranges and median, and the error ba
p value was not significant for all comparisons.elated dyspnea. Further analyses of the PLATO study data ore warranted to explore what clinical factors may contribute
o ticagrelor-related dyspnea.
The reversible nature of ticagrelor-related dyspnea and
he lack of any evidence of cardiac or pulmonary pathology
ssociated with this provide preliminary reassurance about
he nature of this side effect. Although the mechanism for
he dyspnea is unproven, a number of observations support
he hypothesis that adenosine may mediate it. Preliminary
ata have suggested that ticagrelor inhibits adenosine up-
ake into erythrocytes, leading to changes in regional blood
ow similar to those obtained with dipyridamole (6),
nother inhibitor of adenosine reuptake (9). Burki et al. (7)
howed that intravenous infusion of adenosine to healthy
olunteers can induce dyspnea without any associated bron-
hoconstriction, which can occur in asthmatic patients
dministered adenosine. They suggested that adenosine-
nduced dyspnea may be due to stimulation of lung recep-
ors, most likely vagal C fibers. Adenosine administration
an also induce bradycardia and, in both the DISPERSE2
Dose Confirmation Study Assessing Anti-Platelet Effects
monoxide (DLCOSB). (I) Blood oxygen saturation measured by pulse oximetry
w standard deviation, superimposed on scatter plots of individual patients. Thearbon
rs shof AZD6140 vs Clopidogrel in NSTEMI) study and the
P
i
t
c
l
t
t
s
m
b
i
i
S
s
i
a
t
s
p
s
d
d
r
C
D
o
u
d
a
f
w
t
t
l
A
T
B
r
R
D
B
r
R
1
2
3
4
5
6
7
8
9
CBR
V
ED
V
192 Storey et al. JACC Vol. 56, No. 3, 2010
Ticagrelor and Dyspnea July 13, 2010:185–93LATO study, ticagrelor treatment was associated with an
ncreased incidence of ventricular pauses on Holter moni-
oring (3,5), leading to speculation that dyspnea and in-
reased propensity to ventricular pauses induced by ticagre-
or may have the same underlying cause.
Three of 57 patients receiving ticagrelor discontinued
reatment as a result of dyspnea in this study, higher than
he rate of discontinuation due to dyspnea in the PLATO
tudy (3). Again, this may be due to chance or may reflect less
otivation to tolerate the dyspnea in view of the low proba-
ility of therapeutic gain during relatively short-term admin-
stration in a stable population as well as the demands of the
ntensive requirements of the study protocol.
tudy limitations. Patients with recent acute coronary
yndrome, cardiac failure, or significant lung disease includ-
ng asthma were excluded from this study, and further
nalyses and/or studies are warranted to assess the response
o ticagrelor therapy in these groups. The study was not of
ufficient size to assess fully the relationship between dys-
nea and plasma ticagrelor levels. The study was also not of
ufficient size to properly assess whether ticagrelor-related
yspnea is a benign phenomenon, and further analysis of
ata from the PLATO study is required to explore the
elationship between this dyspnea and clinical outcomes.
onclusions
yspnea is commonly associated with ticagrelor therapy,
ften arising during the first week of treatment, and is
sually mild or moderate in severity and often transient
espite continued treatment. Ticagrelor treatment was not
ssociated with any adverse changes in cardiac or pulmonary
unction after 6 weeks of treatment in this study of patients
ho were free of active lung disease at commencement of
he study, including patients who had dyspnea during
ardiac and Pulmonary Assessments atseline and 6 Weeks for Patientseporting Dyspnea Epis de
Table 4
Cardi c and Pulmonary Assessments at
Baseline and 6 Weeks for Patients
Reporting Dyspnea Episode
Parameter
Ticagrelor Clopidogrel
Baseline
(n  22)
6 Weeks
(n  19)
Baseline
(n  6)
6 Weeks
(n  6)
Ejection fraction, % 57 9 58 9 66 7 66 3
NT-proBNP, pmol/ml 147 144 154 221 257 317 260 195
FEV1, l 2.8 0.7 2.8 0.5 2.5 0.6 2.5 0.6
FVC, l 3.9 0.8 3.8 0.8 3.6 0.9 3.6 1.0
FEV1/FVC, % 73 8 74 5 70 7 70 7
VE, l/min 13 4 15 3 13 3 10 4
VT, l/min 1.0 0.3 1.0 0.2 1.0 0.3 1.0 0.5
TLC, l 5.9 1.2 5.8 1.1 5.7 1.0 5.5 1.1
RR, breaths/min 15 2 16 2 14 3 15 1
DLCOSB, % 14 9 13 8 16 7 14 6
SpO2, % 97 2 97 1 98 1 98 1K
alues are mean  SD.
Abbreviations as in Tables 2 and 3.herapy. Further studies of ticagrelor in patients with active
ung disease are now warranted.
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arly Cardiac and Pulmonary Function Assessmentsue to Dyspnea in Ticagrelor-Treated PatientsTable 5 Early Cardi c and Pulmonary Function AssessmentsDue to Dyspnea in Ticagrelor-Treated Patients
Parameter n
Days of
Treatment Baseline Post-Treatment
Ejection fraction, % 5 16 6 66 10 63 3
NT-proBNP, pmol/ml 5 19 9 141 70 126 76
FEV1, l 6 19 8 2.5 0.3 2.5 0.2
FVC, l 6 19 8 3.5 0.4 3.4 0.4
FEV1/FVC 6 19 8 72 8 74 7
RR, breaths/min 5 16 6 15 1 13 2
DLCOSB, % 6 19 8 9 5 9 5
alues are mean  SD.
Abbreviations as in Table 3.ey Words: platelets y coronary disease y thrombosis y pharmacology.
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